Revenue: As of FY2025 Q3, the actual value is USD 15.14 M.EPS: As of FY2025 Q3, the actual value is USD 1.17.EBIT: As of FY2025 Q3, the actual value is USD 157 K.<h3>Real Estate Services</h3><ul><li>Rental Revenues: $1.3 million for the three months ended September 30, 2025, compared to $1.6 million for the same period in 2024, a decrease of 20.5%.</li><li>General and Administrative Expenses: $1.1 million for the three months ended September 30, 2025, compared to $0.9 million for the same period in 2024, an increase of 22.0%.</li><li>Depreciation and Amortization: $0.3 million for the three months ended September 30, 2025, compared to $0.3 million for the same period in 2024.</li><li>Operating Loss: - $0.3 million for the three months ended September 30, 2025, compared to - $0.2 million for the same period in 2024.</li></ul><h3>Healthcare Services</h3><ul><li>Patient Care Revenues: $9.8 million for the three months ended September 30, 2025, compared to $2.6 million for the same period in 2024, an increase of 280.3%.</li><li>Patient Care Expenses: $8.6 million for the three months ended September 30, 2025, compared to $2.2 million for the same period in 2024, an increase of 296.5%.</li><li>General and Administrative Expenses: $1.7 million for the three months ended September 30, 2025, compared to $0.3 million for the same period in 2024, an increase of 411.9%.</li><li>Depreciation and Amortization: $0.1 million for the three months ended September 30, 2025, compared to $0.1 million for the same period in 2024.</li><li>Operating Loss: - $0.3 million for the three months ended September 30, 2025, compared to - $0.1 million for the same period in 2024.</li></ul><h3>Pharmacy Services</h3><ul><li>Pharmacy Revenues: $4.0 million for the three months ended September 30, 2025.</li><li>Cost of Goods Sold: $2.5 million for the three months ended September 30, 2025.</li><li>General and Administrative Expenses: $0.9 million for the three months ended September 30, 2025.</li><li>Depreciation and Amortization: $0.1 million for the three months ended September 30, 2025.</li><li>Operating Loss: - $0.1 million for the three months ended September 30, 2025.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to pursue measures to grow its operations, streamline its cost infrastructure, and increase liquidity. This includes refinancing or repaying debt to reduce interest costs and mandatory principal repayments, increasing future lease revenue through acquisitions and investments in existing properties, modifying the terms of existing leases, replacing certain tenants who default on their lease payment terms, reducing other general and administrative expenses, and integrating the SunLink businesses to reduce duplicative expenses.</li><li>Non-Core Business: The company completed the sale of the Coosa Valley Health and Rehab facility for $10.6 million on November 6, 2025, and plans to use the proceeds for general corporate and other purposes.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $1.0 million for the nine months ended September 30, 2025.</li><li>Net Cash Provided by Investing Activities: $5.3 million for the nine months ended September 30, 2025, including $6.0 million of cash acquired in the SunLink merger.</li><li>Net Cash Used in Financing Activities: - $3.8 million for the nine months ended September 30, 2025, including $2.7 million used to repurchase Series B Preferred shares and $1.3 million for routine payments for senior debt obligations.</li></ul><h3>Unique Metrics</h3><ul><li>Gain on Bargain Purchase: $5.3 million for the three months ended September 30, 2025, resulting from the SunLink merger completed on August 14, 2025.</li></ul><h3>Net Income (Loss)</h3><ul><li>Net Income: $3.4 million for the three months ended September 30, 2025, compared to - $1.0 million for the same period in 2024.</li><li>Net Income: $0.7 million for the nine months ended September 30, 2025, compared to - $2.7 million for the same period in 2024.</li></ul>

REGIONAL HEALTH PROPERTIES INC 10.875% CUM RED PREFD STOCK SER A USD25 | 10-Q: FY2025 Q3 Revenue: USD 15.14 M